N4 Pharma PLC Result of AGM
23 Maggio 2024 - 1:19PM
RNS Regulatory News
RNS Number : 6939P
N4 Pharma PLC
23 May 2024
N4 Pharma
plc
("N4
Pharma" or the "Company")
Result of Annual General
Meeting
N4 Pharma Plc (AIM: N4P), the
specialist pharmaceutical company developing Nuvec®, a novel
delivery system for cancer treatments and vaccines, is pleased to
announce that at its annual general meeting ("AGM"), held earlier
today, all resolutions were duly passed.
|
Resolution
|
For
|
For%
|
Against
|
Against%
|
Total
|
Witheld
votes*
|
|
Ordinary Resolution 1
To receive the annual report and
audited accounts for the year
ended 31 December 2023
|
20,612,844
|
99.93%
|
13,980
|
0.07%
|
20,626,824
|
296,841
|
|
Ordinary Resolution 2
To re-elect Nigel Theobald as a
Director of the Company
|
20,605,744
|
99.32%
|
141,080
|
0.68%
|
20,746,824
|
176,841
|
|
Ordinary Resolution 3
To re-elect David Templeton as a
Director of the Company
|
20,605,744
|
99.32%
|
141,080
|
0.68%
|
20,746,824
|
176,841
|
|
Ordinary Resolution 4
To re-appoint Saffery Champness LLP
as the Companyʼs auditor
and to authorise the Directors to
determine their remuneration
|
20,605,644
|
99.32%
|
140,980
|
0.68%
|
20,746,624
|
177,041
|
|
Ordinary Resolution 5
To authorise the Directors to allot
shares
|
20,559,085
|
99.10%
|
187,539
|
0.90%
|
20,746,624
|
177,041
|
|
Special Resolution 6
To disapply pre-emption
rights
|
20,506,310
|
99.00%
|
207,439
|
1.00%
|
20,713,749
|
209,916
|
*Please note a vote withheld is not
a vote in law and is not counted in the calculation of votes
validly cast for or against a resolution.
For
more information please contact:
|
N4
Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive
Director
|
investors.n4pharma.com
|
|
SP
Angel Corporate Finance
LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe/Kasia
Brzozowska (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob
Rees (Corporate Broking)
|
Tel: +44(0)20 3470 0470
|
|
InvestorHub
Engage with us directly at N4 Pharma
Investor Hub
|
Sign up at investors.n4pharma.com
https://investors.n4pharma.com/link/Ky0AZe
|
|
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
|
Tel: +44(0)20 3657 0050
|
About N4 Pharma
N4 Pharma is a specialist
pharmaceutical company developing a novel delivery system for
oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to
partner with companies developing novel antigens in these fields to
use Nuvec® as the delivery vehicle for these antigens. As these
products progress through pre‐clinical and clinical programs, N4
Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the
market.
For further information on the
Company visit www.n4pharma.com or sign up at www.investors.n4pharma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RAGBBGDUIBDDGSX
Grafico Azioni N4 Pharma (LSE:N4P)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni N4 Pharma (LSE:N4P)
Storico
Da Dic 2023 a Dic 2024
